

# Contemporary Management of Patients With Systemic Lupus Erythematosus: A Case-based Approach



## Bibliography List

Akhavan PS, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. *J Rheumatol*. 2013;40:831-841

Amital H, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? *Ann Rheum Dis*. 2010;69:1155–1157

Apostolopoulos D, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. *Lancet Rheumatol*. 2020;2:e24-30

Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78:1151–1159

Attar SM, Siddiqui AM. Vitamin d deficiency in patients with systemic lupus erythematosus. *Oman Med J*. 2013;28:42–47

Bennett JK et al. The role of patient attachment and working alliance on patient adherence, satisfaction, and health-related quality of life in lupus treatment. *Patient Educ Couns*. 2011;85:53–59

Broder A, et al. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. *J Rheumatol*. 2013;40:30-33

Brunner HI, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. *Arthritis Rheum*. 2008;58:556-562

Chavatza K, et al. Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. *Ann Rheum Dis*. 2021;80:1175-1182

Choi ST, et al. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. *Clin Exp Rheumatol*. 2012;30:664-672

Cooper GS, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. *Lupus*. 2002;11:161-167

Davidson JE, et al. Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. *Lupus Sci Med*. 2018;5:e000237

Falasinu T, et al. The representation of gender and race/ethnic groups in randomized clinical trials of individuals with systemic lupus erythematosus. *Curr Rheumatol Rep*. 2018;20:20

Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78:736-745

# Contemporary Management of Patients With Systemic Lupus Erythematosus: A Case-based Approach



Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. *Arthritis Rheum.* 2013;65:753-763

Fernando M, Isenberg D. How to monitor SLE in routine clinical practice – PMC. *Ann Rheum. Dis* 2005;64:524-527

Franklyn K, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Ann Rheum Dis.* 2016;75:1615-1621

Grootscholten C, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. *Qual Life Res.* 2003;12:635-644

Hassanalilou T, et al. Role of vitamin D deficiency in systemic lupus erythematosus incidence and aggravation. *Auto Immun Highlights.* 201;9:1

Hersh AO, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. *Arthritis Rheum.* 2009;61:13-20

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997;40:1725

Izmirly PM, et al. Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. *Lupus Sci Med.* 2021;8:e000614

Kawka L, et al. Fatigue in systemic lupus erythematosus: An update on its impact, determinants and therapeutic management. *J Clin Med.* 2021;10:3996

Kernder A, et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. *Lupus.* 2021;30:431-438

Lambers WM, et al. Incomplete systemic lupus erythematosus: What remains after application of American College of Rheumatology and systemic lupus international collaborating clinics criteria? *Arthritis Care Res.* 2020;72:607-614

Lampa J. Pain without inflammation in rheumatic diseases. *Best Pract Res Clin Rheumatol.* 2019;33:101439

Leong KP, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). *Rheumatology.* 2005;44:1267-1276

Lim SS, et al. Racial disparities in mortality associated with systemic lupus erythematosus – Fulton and DeKalb counties, Georgia, 2002-2016. *MMWR Morb Mortal Wkly Rep.* 2019;68:419-422

Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Medicine.* 2022;28:2124-2132

Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. *Am J Epidemiol.* 2012;176:708-719

# Contemporary Management of Patients With Systemic Lupus Erythematosus: A Case-based Approach



Maningding E, et al. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: The California Lupus Surveillance Project. *Arthritis Care Res (Hoboken)*. 2020;72:622-629

McElhone K, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. *Arthritis Care Res*. 2007;57:972-979

Moe SR, et al. Long-term outcome of systemic lupus erythematosus (SLE); data from the large population-based southeast SLE cohort (Nor-SLE). *Ann Rheum Dis*. 2022;81(Suppl 1):1050-1051

Mok C, et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. *Lupus*. 2012;21:36-42.

Morand EF, et al. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. *Ann Rheum Dis*. 2023;82:639-645

Morand E, et al. LB0004 efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: A phase 2, randomized, double-blind, placebo-controlled study. *Ann Rheum Dis*. 2022;81:209

Oon S, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78:629-633

Parikh SV, et al. Update on Lupus Nephritis: Core Curriculum 2020. *Am J Kidney Dis*. 2020;76:265-281

Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012;64:2677-2686

Petri M, et al. Vitamin D in SLE: Modest association with disease activity and urine protein/creatinine ratio. *Arthritis Rheum*. 2013;65:1865-1871.

Piga M, et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. *Arthritis Res Ther*. 2017;19:247

Piga M, et al. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. *Rheumatology (Oxford)*. 2020;59:2272-2281

Pincus T, et al. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. *Rheum Dis Clin North Am*. 2009;35:773-778

Pisetsky DS, et al. A novel system to categorize the symptoms of systemic lupus erythematosus. *Arthritis Care Res*. 2019;71(6):735-741

Pisetsky DS, et al. The categorization of pain in systemic lupus erythematosus. *Rheum Dis Clin North Am*. 2021;47:215-228

Rovin BH, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) : a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2021;397:2070-2080

# Contemporary Management of Patients With Systemic Lupus Erythematosus: A Case-based Approach



Ruiz-Irastorza G, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis*. 2010;69:20

Sakthiswary R, et al. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. *Lupus*. 2014;23:225-235

Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. *Clin Dev Immunol*. 2012;2012:604892.

Sharma C, et al. Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. *Arthritis Care Res*. 2020;72:447-451

Sheikh SZ, et al. The state of lupus clinical trials: minority participation needed. *J Clin Med*. 2019;8:1245

Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1982;25:1271-1277

Thamer M, et al. Prednisone, lupus activity, and permanent organ damage. *J Rheumatol*. 2009;36:560-564

Tucker LB, et al. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. *Br J Rheumatol*. 1995; 34:866-872

Ugarte-Gil MF, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. *Lupus Sci Med*. 2021;8:e000590

Urowitz MB, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. *Arthritis Care Res*. 2012;64:132-137

Urowitz MB, et al. Impact of belimumab on organ damage in systemic lupus erythematosus. *Arthritis Care Res*. 2022;74:1822-1828

Werth VP, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. *N Engl J Med*. 2022;387:321-331

Zheng ZH, et al. Predictors of survival in Chinese patients with lupus nephritis. *Lupus*. 2012;21:1049-1056